- Home
- DHF vs IPHA Comparison
DHF vs IPHA Comparison
Compare DHF & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- IPHA
- Stock Information
- Founded
- DHF 1998
- IPHA 1999
- Country
- DHF United States
- IPHA France
- Employees
- DHF N/A
- IPHA N/A
- Industry
- DHF Finance Companies
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- DHF Finance
- IPHA Health Care
- Exchange
- DHF Nasdaq
- IPHA Nasdaq
- Market Cap
- DHF 188.4M
- IPHA 148.3M
- IPO Year
- DHF N/A
- IPHA 2019
- Fundamental
- Price
- DHF $2.62
- IPHA $1.69
- Analyst Decision
- DHF
- IPHA Strong Buy
- Analyst Count
- DHF 0
- IPHA 1
- Target Price
- DHF N/A
- IPHA $11.50
- AVG Volume (30 Days)
- DHF 451.1K
- IPHA 49.9K
- Earning Date
- DHF 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- DHF 7.65%
- IPHA N/A
- EPS Growth
- DHF N/A
- IPHA N/A
- EPS
- DHF N/A
- IPHA N/A
- Revenue
- DHF N/A
- IPHA $36,202,722.00
- Revenue This Year
- DHF N/A
- IPHA N/A
- Revenue Next Year
- DHF N/A
- IPHA $101.65
- P/E Ratio
- DHF N/A
- IPHA N/A
- Revenue Growth
- DHF N/A
- IPHA N/A
- 52 Week Low
- DHF $2.06
- IPHA $1.29
- 52 Week High
- DHF $2.39
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- DHF 57.34
- IPHA 42.95
- Support Level
- DHF $2.53
- IPHA $1.60
- Resistance Level
- DHF $2.62
- IPHA $1.87
- Average True Range (ATR)
- DHF 0.03
- IPHA 0.13
- MACD
- DHF 0.01
- IPHA -0.04
- Stochastic Oscillator
- DHF 100.00
- IPHA 16.67
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.